A Randomized, Open-Label, Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profile, Safety, and Tolerability of Peginterferon Beta-1a Delivered by Pre-filled Syringe or Autoinjector in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2015
At a glance
- Drugs Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Biogen Idec
- 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.